



--- PRESS RELEASE ---

OptiCell Solutions AB delivers first cell material to Karolinska Institutet under research collaboration

Huddinge, Sweden 05-FEB-2026

OptiCell Solutions today announces the successful delivery of its first cell material to Karolinska Institutet, marking an important milestone in the research collaboration agreement entered on 29 October 2025.

The delivery is fully in line with the terms of the two-year collaboration and represents the first step in supplying apheresis-generated cell material to support research and development of advanced cell and gene therapies. The cell products will be used in pre-GMP validation of manufacturing processes, including gene modification for immunotherapy applications.

“This first delivery is an important operational and scientific milestone for OptiCell Solutions,” says Jarmo Henriksson, CEO of OptiCell Solutions. “It demonstrates our ability to translate agreements into reliable execution and to provide researchers at Karolinska Institutet with high-quality starting material that is essential for advancing next-generation cell and gene therapies.”

Ensuring consistent access to well-characterized starting material remains a key challenge in the development of advanced therapy medicinal products (ATMPs). By combining specialized apheresis expertise with a strong commitment to ethical research practices, OptiCell Solutions aims to support academic and industrial partners in overcoming this bottleneck.

This delivery further strengthens OptiCell Solutions’ role as a trusted partner to leading academic research institutions working at the forefront of immunotherapy and precision medicine.

--- END PRESS RELEASE ---

For more information, please contact

General Manager, Jarmo Henriksson, +46 (0) 73 699 48 37, jarmo.henriksson@opticellsolutions.com

Chairman of the board, Peter Rybäck, +46 (0) 73 849 07 96, peter.ryback@opticellsolutions.com

About OptiCell Solutions

Founded in 2024, OptiCell Solutions AB specializing in the field of apheresis collection for Cell and Gene Therapy (CGT). By using our advanced apheresis technology, we can collect large quantities of specific donor cells, significantly advancing applications within in the CGT.

Located near the Karolinska University Hospital in Huddinge we aim to bridge the gap in resources by offering innovative solutions that enhance the availability of essential cells for cutting-edge research and life-saving therapies. With our deep expertise in apheresis technology and a strong commitment to ethical research practices, we are dedicated to improving patient outcomes and supporting the development of next-generation therapies for cancer care, autoimmune diseases, and other severe medical conditions.

At OptiCell Solutions, we strive to be at the forefront of medical innovation, providing the tools and services necessary to accelerate the transition to more effective and patient-centred care. For more information visit our website, www.opticellsolutions.com and follow us at [LinkedIn](#).